Cutaneous Melanoma ARTISTRY-6, Cohorts 3 & 4
Dosing: Nemvaleukin (LFIV) Monotherapy and Combination with Pembrolizumab Anticipated Program Milestone: Preliminary data readout for cohort 3 (monotherapy) expected in 1H2025 and for cohort 4 (combination therapy) in 2H 2025 (subject to patient enrollment) >> Learn more about Nemvaleukin Alfa >> Visit the ARTISTRY-6 study website
Read More
Mucosal Melanoma ARTISTRY-6, Cohort 2
Dosing: Nemvaleukin (IV) Monotherapy (Potentially Registrational) Anticipated Program Milestone: Top-line data readout expected in 1H 2025 >> Learn more about Nemvaleukin Alfa >> Visit the ARTISTRY-6 study website
Read More
Platinum-Resistant Ovarian Cancer ARTISTRY-7
Dosing: Nemvaleukin (IV) Monotherapy and Combination with Pembrolizumab (Potentially Registrational) Anticipated Program Milestone: Interim readout expected in Q1 2025, with final OS projected in 1H 2026 (subject to event accrual) >> Learn more about Nemvaleukin Alfa >> Visit the ARTISTRY-7 study website
Read More